Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359086 · ClinicalTrials.gov registry record · Phase 2
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
A Phase 2 study, sponsored by Mirati Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00359086 is a Phase 2 study that has completed, run by Mirati Therapeutics. The registered enrollment target is 74 participants.
The verdict
NCT00359086, a Phase 2 study, has completed, sponsored by Mirati Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
Interventions
- DRUG MGCD0103
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2006-08 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359086
The ClinicalTrials.gov registry entry for NCT00359086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGCD0103 is the first listed.
NCT00359086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00359086 about?
NCT00359086 is a clinical study titled "Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma". In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with relapsed and refractory lymphoma.
What is the current status of trial NCT00359086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2006-08. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00359086?
The interventions under investigation include: MGCD0103 (DRUG).
Who is sponsoring clinical trial NCT00359086?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.